Sartorius AGSARTF 85 5-Year Yield-on-Cost % is 0.68 as of Jul. 02, 2026, which is 3% below its 10-year median of 0.70. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $274.62 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 328 Medical Devices & Instruments companies, Sartorius AG ranks worse than 86.59% on this metric.
Sartorius AG's yield on cost for the quarter that ended in Mar. 2026 was 0.68.
The historical rank and industry rank for Sartorius AG's 5-Year Yield-on-Cost % or its related term are showing as below:
SARTF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14 Med: 0.7 Max: 1.88
Current: 0.68
During the past 13 years, Sartorius AG's highest Yield on Cost was 1.88. The lowest was 0.14. And the median was 0.70.
SARTF's 5-Year Yield-on-Cost % is ranked worse than 86.59% of 328
companies
in the Medical Devices & Instruments industry
Industry Median: 2.425
vs SARTF: 0.68
Sartorius AG (OTCPK:SARTF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sartorius AG 5-Year Yield-on-Cost % Related Terms
SARTF vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sartorius AG is calculated as
Sartorius AG (SARTF) has a 5-Year Yield-on-Cost % of 0.68 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sartorius AG and its competitors. This is near median its historical median of 0.70. Over the past decade, Sartorius AG's 5-Year Yield-on-Cost % has ranged from 0.14 to 1.88. According to the industry distribution chart, Sartorius AG ranks #284 out of 328 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is Sartorius AG's 5-Year Yield-on-Cost % too high?
Sartorius AG's current 5-Year Yield-on-Cost % of 0.68 is near median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.88. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.43. Sartorius AG's value of 0.68 is 72% below this industry median. Based on the distribution chart, Sartorius AG ranks #284 out of 328 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #284 out of 328 companies for 5-Year Yield-on-Cost %. This places Sartorius AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Sartorius AG's value of 0.68 is 72% below this benchmark. Historically, Sartorius AG's own 5-Year Yield-on-Cost % has ranged from 0.14 to 1.88 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 2.43, Sartorius AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current 5-Year Yield-on-Cost % of 0.68 is 72% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current 5-Year Yield-on-Cost % is 0.68, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $274.62, compared to a current price of $212.80 — trading 22.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.68, which is near median its 10-year median of 0.70 and 72% below the Medical Devices & Instruments industry median of 2.43. Sartorius AG's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 5-Year Yield-on-Cost % is 0.68 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.5% below its estimated GF Value™ of $274.62.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
5-Year Yield-on-Cost %: 0.68 (near median its 10-year median of 0.70)
GF Value™: $274.62 vs. price of $212.80 (22.5% below fair value)
Industry Position: 72% below the Medical Devices & Instruments median (#284 of 328)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 